| Code | CSB-RA011867MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to natalizumab, targeting integrin alpha-4 (ITGA4, CD49d), a cell surface receptor that forms heterodimers with integrin beta-1 or beta-7. ITGA4 plays a critical role in cell adhesion and migration by mediating leukocyte trafficking across the blood-brain barrier and into inflamed tissues through interactions with vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Dysregulated ITGA4 expression and function are implicated in autoimmune and inflammatory conditions, particularly multiple sclerosis and inflammatory bowel disease, where aberrant lymphocyte migration contributes to tissue damage and disease progression.
Natalizumab is a humanized IgG4 monoclonal antibody approved for treating relapsing forms of multiple sclerosis and Crohn's disease by blocking ITGA4-mediated adhesion and transmigration of leukocytes. This biosimilar antibody serves as a valuable research tool for investigating integrin-mediated cellular adhesion mechanisms, leukocyte trafficking pathways, and neuroinflammatory processes. It supports studies exploring immune cell migration, autoimmune disease pathogenesis, and potential therapeutic interventions targeting the ITGA4 pathway.
There are currently no reviews for this product.